A spider that can kill you in 15 minutes might save your life after a heart attack.
Scientists at the University of Queensland have transformed venom from the K’gari funnel-web spider into a synthetic drug that prevents up to 80% of tissue damage during heart attacks and strokes. Human trials begin later this year, marking the first time any drug of this type has made it this far.
The breakthrough comes at a critical time — someone in America has a heart attack every 40 seconds.
The 20,000-Year-Old Secret
On K’gari Island off Australia’s eastern coast, funnel-web spiders have been isolated for 20,000 years.
This isolation created something extraordinary.
Their venom evolved differently from mainland cousins — it’s six times more potent than the infamous Sydney funnel-web. But hidden within this lethal cocktail of 3,000+ peptides was Hi1a, a molecule that hijacks the very signals that kill heart and brain cells during medical emergencies.
Professor Glenn King discovered it almost by accident while cataloging spider venoms at the University of Queensland.
“Animal venoms are a treasure trove of bioactive compounds,” King explained in his research findings.
How Spider Venom Stops Death?
When you have a heart attack, your cells start dying within minutes.
Here’s what happens: Blood flow stops. Oxygen disappears. Cells switch to emergency mode, producing lactic acid. The tissue becomes dangerously acidic. This acidity triggers a “death signal” telling cells to self-destruct.
You lose 2 million neurons every minute during a stroke.
Hi1a blocks this death signal completely.
In laboratory tests with mice, Hi1a reduced brain damage by 80% — even when given four hours after a stroke began. For comparison, current stroke treatments must be administered within 60 minutes to be effective.
The drug works by targeting acid-sensing ion channels, the cellular gateways that normally trigger the death cascade.
“We found Hi1a only interacts with cells in the injured zone during an attack,” says heart disease expert Associate Professor Nathan Palpant. “It doesn’t bind to healthy regions of the heart.”
Racing Against the Clock
Every year, 805,000 Americans have heart attacks. Another 795,000 suffer strokes.
For people in rural areas, the journey to a hospital can take hours. By then, the damage is done. Brain cells are dead. Heart muscle is destroyed. Lives are forever changed.
Hi1a could change everything.
First responders could administer the drug in ambulances. Rural clinics could stock it. Nursing homes could have it on hand. The window for preventing permanent damage would extend from minutes to hours.
We visited the University of Queensland lab where researchers are preparing for human trials.
From Venom to Medicine: The $23 Million Journey
Creating a drug from spider venom isn’t simple.
First, researchers must collect the spiders. On K’gari Island, they dig up sandy burrows where the arachnids hide. Each spider produces only tiny amounts of venom — mere drops that must be carefully extracted with pipettes.
Then comes years of analysis. King’s team tested thousands of peptides before identifying Hi1a. They created synthetic versions. Ran safety studies. Compared it to existing drugs.
Hi1a matched the performance of cariporide — the only similar drug to reach Phase 3 trials before failing due to side effects.
But Hi1a appears to avoid those problems entirely.
Infensa Bioscience, the startup founded by King and Palpant, raised $23 million in 2022 to bring Hi1a to market. Independent safety studies have now cleared the path for human trials.
“Most deaths from cardiovascular disease are caused by heart attacks and strokes, yet there are no drugs on the market that prevent the damage they cause,” explains Infensa CEO Mark Smythe.
What Happens Next?
Human trials begin later this year with acute heart attack patients.
If successful, the drug could reach first responders within five years. But the implications stretch far beyond emergency medicine.
The same compound shows promise for preserving donor hearts during transplantation — potentially increasing the number of viable organs available. It might work for other conditions involving oxygen deprivation. The 3,000 other peptides in funnel-web venom could hold treatments for chronic pain, neurological disorders, even endometriosis.
Animal venoms have already revolutionized medicine. The diabetes drug Ozempic came from Gila monster venom. Now, a spider that evolved in isolation on an Australian island might save millions of lives worldwide.
We researched the latest updates from the research team — they remain cautiously optimistic.
“This could give people a much better chance of coming through ischemia with a better quality of life,” Palpant stated in recent regulatory filings.
The spider known to the Butchulla people as “mudjar nhiling guran” — long-toothed spider — has been keeping this secret for millennia.
Soon, we’ll know if it can truly stop death in its tracks.
The Bottom Line
A molecule from one of the world’s deadliest spiders could become the first drug to prevent heart attack and stroke damage. With human trials starting this year and $23 million in funding secured, Hi1a represents the most promising breakthrough in emergency cardiac care in decades. For the 1.6 million Americans who suffer heart attacks and strokes annually, this spider venom compound could mean the difference between permanent disability and full recovery.
Related Articles
